FOXO Technologies Inc. Completes Stock Split
FOXO Technologies Inc. (NYSE American: FOXO) is making strides to enhance its share performance. The company recently completed a 1 for 10 reverse stock split effective at 4:01 PM Eastern Time. Starting the day after this significant move, FOXO's shares have opened for trading on a post-split basis, continuing under the same FOXO ticker symbol.
Understanding the Reverse Stock Split
In this reverse split, every ten shares of FOXO’s common stock that were outstanding before the split have been consolidated into one share. Importantly, the nominal par value of these shares remains unchanged at $0.0001, and no fractional shares will be created. Instead, shareholders with fractional shares will be compensated with a whole share adjustment.
Impact on Share Structure
Before the split, FOXO had roughly 38.7 million shares in circulation. Post-split, this number will significantly reduce to approximately 3.87 million shares. This reduction helps streamline the share structure and may improve the trading dynamics for investors and stakeholders.
Adjustments for Other Securities
Not just common shares, but all outstanding preferred shares, stock options, and warrants will also undergo adjustments commensurate with the reverse stock split. This ensures that the proportional relationship among various equity instruments remains intact, reflecting the new structure in the market.
Operational Changes and Shareholder Communication
To facilitate the transition, FOXO has partnered with Continental Stock Transfer & Trust Company to manage the exchange process for stock certificates. Shareholders of record will receive a letter with instructions on how to exchange their stock certificates, ensuring clarity and assistance during this transition.
Broker-Handled Shares
For those who hold shares through brokers, adjustments will occur automatically according to the specific processes of different brokerage firms. Shareholders will not need to take any extra steps to participate in this transition.
Corporate Governance and Approval Process
The decision to implement a reverse stock split was made by FOXO’s board of directors and received overwhelming support from shareholders during the Annual Meeting. This reflects confidence in creating a more robust company profile and investor appeal.
About FOXO Technologies Inc.
FOXO Technologies operates through its three distinct subsidiaries, focusing on enhancing health outcomes and service effectiveness. One of its branches, Rennova Community Health, owns and operates a critical access hospital, while Myrtle Recovery Centers specializes in behavioral health services. Foxo Labs is dedicated to pioneering biotechnology initiatives that look at improving human health and well-being.
Engaging with FOXO Technologies
For investors and interested parties wanting to learn more about FOXO Technologies and its innovative services, the company encourages visits to its official website for up-to-date information and strategic insights into its operations.
Frequently Asked Questions
What is a reverse stock split?
A reverse stock split is a corporate action where a company reduces the number of its outstanding shares, increasing the share price proportionally but keeping the overall value the same.
Why did FOXO Technologies perform a reverse stock split?
The reverse stock split aims to improve the company's market perception and stock liquidity, potentially attracting additional investors.
What does this mean for existing shareholders?
Existing shareholders will see a decrease in the number of shares they hold, but the value of their investment should remain constant, adjusted to reflect the new share count.
How can shareholders exchange their stock certificates?
Shareholders will receive instructions from the transfer agent, Continental, on how to exchange their certificates. Those with shares held through brokers will have their holdings adjusted automatically.
What is FOXO Technologies' business focus?
FOXO Technologies focuses on health services through its subsidiaries, aiming to innovate in the medical and biotechnology sectors to enhance human health.
